EyePoint Appoints Michael Campbell as Chief Commercial Officer

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced th ...